ArticleMolecular oncology2022

Vandetanib drives growth arrest and promotes sensitivity to imatinib in chronic myeloid leukemia by targeting ephrin type-B receptor 4.

Weina Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.